Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Treatment with risankizumab for 12 weeks (three months) induced both clinical and endoscopic remission in people with Crohn’s disease, a type of inflammatory bowel disease (IBD), new Phase 3 clinical ... Read more
The anti-inflammatory medication Zeposia (ozanimod) is under review in the European Union as a treatment for adults with moderately to severely active ulcerative colitis. The European Medicines Agency has validated ... Read more
Pterostilbene (PSB), a compound found in blueberries, can reduce the inflammatory activity of immune cells and limit colon inflammation in mice, a new study shows. The findings suggest that PSB ... Read more
Abnormalities in intestinal stem cell niches may predict recurrence in Crohn’s disease, a new study suggests. These irregularities may result from problems with mitochondria — the so-called powerhouse of cells ... Read more
People with ulcerative colitis may benefit from the experimental oral therapy BBT-401, suggest early data from an ongoing Phase 2 clinical trial that also supports its good safety profile. BBT-401 is ... Read more
The European Commission has approved a subcutaneous (under-the-skin) formulation of Entyvio (vedolizumab) for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). This ... Read more
A controlled-release version of etrasimod could limit the changes in heart rate linked to an initial dose of this investigational medication, according to topline clinical trial data announced by Arena ... Read more